141 results on '"Lam, Patrick Y.S."'
Search Results
2. N-in-1 Dosing Pharmacokinetics in Drug Discovery: Experience, Theoretical and Practical Considerations
3. Orally bioavailable amine-linked macrocyclic inhibitors of factor XIa
4. Structure based design of macrocyclic factor XIa inhibitors: Discovery of cyclic P1 linker moieties with improved oral bioavailability
5. Counteracting HIV-1 protease drug resistance: Structural analysis of mutant proteases complexed with XV638 and SD146, cyclic urea amides with broad specifities
6. Calculated and experimental low-energy conformations of cyclic urea HIV protease inhibitors
7. Molecular basis of HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with cyclic urea inhibitors
8. Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors
9. Macrocyclic inhibitors of Factor XIa: Discovery of alkyl-substituted macrocyclic amide linkers with improved potency
10. Novel phenylalanine derived diamides as Factor XIa inhibitors
11. Solid supported [formula omitted] CN cross-coupling reactions
12. Orally bioavailable factor Xa inhibitors containing alpha-substituted gem-dimethyl P4 moieties
13. 2-Amino-1,3,4-thiadiazoles in the 7-hydroxy-N-neopentyl spiropiperidine indolinyl series as potent P2Y1 receptor antagonists
14. Identification of 1-{2-[4-chloro-1′-(2,2-dimethylpropyl)-7-hydroxy-1,2-dihydrospiro[indole-3,4′-piperidine]-1-yl]phenyl}-3-{5-chloro-[1,3]thiazolo[5,4-b]pyridin-2-yl}urea, a potent, efficacious and orally bioavailable P2Y1 antagonist as an antiplatelet agent
15. Potent P2Y1 urea antagonists bearing various cyclic amine scaffolds
16. 2-Aminothiazole based P2Y1 antagonists as novel antiplatelet agents
17. New azole antagonists with high affinity for the P2Y1 receptor
18. Discovery of diarylurea P2Y1 antagonists with improved aqueous solubility
19. Copper-promoted C-N bond cross-coupling with hypervalent aryl siloxanes and room-temperature N-arylation with aryl iodide
20. Highly efficacious factor Xa inhibitors containing α-substituted phenylcycloalkyl P4 moieties
21. Achieving structural diversity using the perpendicular conformation of alpha-substituted phenylcyclopropanes to mimic the bioactive conformation of ortho-substituted biphenyl P4 moieties: Discovery of novel, highly potent inhibitors of Factor Xa
22. Structure–activity relationships of anthranilamide-based factor Xa inhibitors containing piperidinone and pyridinone P4 moieties
23. Sulfonamidolactam inhibitors of coagulation factor Xa
24. Structure–activity relationship and pharmacokinetic profile of 5-ketopyrazole factor Xa inhibitors
25. NMR evidence for the displacement of a conserved interior water molecule in HIV protease by a non-peptide cyclic urea-based inhibitor
26. SAR and X-ray structures of enantiopure 1,2-cis-(1R,2S)-cyclopentyldiamine and cyclohexyldiamine derivatives as inhibitors of coagulation Factor Xa
27. Design, structure–activity relationship, and pharmacokinetic profile of pyrazole-based indoline factor Xa inhibitors
28. Amino(methyl) pyrrolidines as novel scaffolds for factor Xa inhibitors
29. Enantiopure five-membered cyclicdiamine derivatives as potent and selective inhibitors of factor Xa. Improving in vitro metabolic stability via core modifications
30. Pyrazole-based factor Xa inhibitors containing N-arylpiperidinyl P4 residues
31. Effects of the Factor Xa Inhibitor Apixaban on Venous Thrombosis and Hemostasis in Rabbits.
32. Preclinical Pharmacokinetic and Metabolism of Apixaban, a Potent and Selective Factor Xa Inhibitor.
33. Discovery of potent, efficacious, and orally bioavailable inhibitors of blood coagulation factor Xa with neutral P1 moieties
34. Preparation of 1-(3-aminobenzo[d]isoxazol-5-yl)-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-ones as potent, selective, and efficacious inhibitors of coagulation factor Xa
35. 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[2′-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa
36. Preparation of 1-(4-methoxyphenyl)-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-ones as potent, selective and bioavailable inhibitors of coagulation factor Xa
37. Aminobenzisoxazoles with biaryl P4 moieties as potent, selective, and orally bioavailable factor Xa inhibitors
38. Preparation of 1-(4-methoxyphenyl)-1 H-pyrazolo[4,3- d]pyrimidin-7(6 H)-ones as potent, selective and bioavailable inhibitors of coagulation factor Xa
39. Preparation of 1-(3-aminobenzo[ d]isoxazol-5-yl)-1 H-pyrazolo[4,3- d]pyrimidin-7(6 H)-ones as potent, selective, and efficacious inhibitors of coagulation factor Xa
40. Copper-promoted/catalyzed CN and CO bond cross-coupling with vinylboronic acid and its utilities
41. Copper promoted CN and CO bond cross-coupling with phenyl and pyridylboronates
42. Discovery of 3-Amino-4-Chlorophenyl P1 as a novel and potent benzamidine mimic via solid-phase synthesis of an isoxazoline library
43. Nonbenzamidine isoxazoline derivatives as factor Xa inhibitors
44. Nonbenzamidine tetrazole derivatives as factor Xa inhibitors
45. N-Arylation of α-aminoesters with p-tolylboronic acid promoted by copper(II) acetate
46. Copper-promoted CN bond cross-coupling with phenylstannane
47. Copper-catalyzed general CN and CO bond cross-coupling with arylboronic acid
48. Synthesis and SAR of benzamidine factor Xa inhibitors containing a vicinally-substituted heterocyclic core
49. α-Nitrogen activating effect in the room temperature copper-promoted N-arylation of heteroarylcarboxamides with phenyl siloxane or p-toluylboronic acid
50. Solid supported CN cross-coupling reactions
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.